Lilly's 14th acquisition of the year is a little-known blood cancer biotech
Eli Lilly has been on a shopping spree this year thanks to its GLP-1-driven revenue, and its 14th acquisition of 2026 is …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Source link







